

# Linda M Liao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4336378/publications.pdf>

Version: 2024-02-01

193  
papers

24,894  
citations

13865

67  
h-index

7348

152  
g-index

206  
all docs

206  
docs citations

206  
times ranked

30046  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. <i>Neuro-Oncology</i> , 2022, 24, 1020-1028.	1.2	12
2	Human Astrocytes Exhibit Tumor Microenvironment-, Age-, and Sex-Related Transcriptomic Signatures. <i>Journal of Neuroscience</i> , 2022, 42, 1587-1603.	3.6	24
3	Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI. <i>Scientific Reports</i> , 2022, 12, 1078.	3.3	5
4	Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease. <i>Frontiers in Oncology</i> , 2022, 12, 849993.	2.8	1
5	Diversity in Neurosurgical Recruitment and Training in the United States: A Systematic Review. <i>World Neurosurgery</i> , 2022, 162, 111-117.e1.	1.3	7
6	Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study. <i>Cancers</i> , 2022, 14, 2520.	3.7	2
7	Voxelwise and Patientwise Correlation of <sup>18</sup> F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes. <i>Journal of Nuclear Medicine</i> , 2021, 62, 319-325.	5.0	13
8	Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas. <i>Neuroradiology</i> , 2021, 63, 857-868.	2.2	7
9	FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab017.	0.7	6
10	Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1094-1104.	6.3	16
11	Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET. <i>Cancer Imaging</i> , 2021, 21, 27.	2.8	13
12	Preferential tumor localization in relation to 18F-FDOPA uptake for lower-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2021, 152, 573-582.	2.9	2
13	Developing a Professionalism and Harassment Policy for Organized Neurosurgery. <i>Neurosurgery</i> , 2021, 88, 1038-1039.	1.1	3
14	The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749.	12.8	47
15	Glioblastoma: Molecular Mechanisms and Clinical Trials. <i>Neurosurgery Clinics of North America</i> , 2021, 32, xiii.	1.7	1
16	Brain Tumor Vaccines. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 225-234.	1.7	4
17	NF1 mutation drives neuronal activity-dependent initiation of optic glioma. <i>Nature</i> , 2021, 594, 277-282.	27.8	91
18	Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1022-1029.	2.2	5

#	ARTICLE	IF	CITATIONS
19	Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma. <i>Radiotherapy and Oncology</i> , 2021, 161, 140-147.	0.6	10
20	Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871.	7.7	34
21	Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021, 23, 356-375.	1.2	59
22	Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. <i>Nature Communications</i> , 2021, 12, 6938.	12.8	93
23	“Aerobic glycolytic imaging” of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging. <i>NeuroImage: Clinical</i> , 2021, 32, 102882.	2.7	8
24	Developing a professionalism and harassment policy for organized neurosurgery. <i>Journal of Neurosurgery</i> , 2021, 134, 1-2.	1.6	1
25	Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. <i>Scientific Reports</i> , 2020, 10, 11922.	3.3	23
26	Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 149, 337-346.	2.9	5
27	Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. <i>Scientific Reports</i> , 2020, 10, 14819.	3.3	13
28	Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. <i>Neurosurgery</i> , 2020, 87, 931-938.	1.1	14
29	The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 11085-11096.	7.1	33
30	1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine treatment after brain irradiation preserves cognitive function in mice. <i>Neuro-Oncology</i> , 2020, 22, 1484-1494.	1.2	6
31	Editorial. Sexual harassment in neurosurgery: #UsToo. <i>Journal of Neurosurgery</i> , 2020, , 1-3.	1.6	2
32	Results From the CheckMate 143 Clinical Trial. <i>JAMA Oncology</i> , 2020, 6, 987.	7.1	11
33	Continuous improvement in patient safety and quality in neurological surgery: the American Board of Neurological Surgery in the past, present, and future. <i>Journal of Neurosurgery</i> , 2020, , 1-7.	1.6	2
34	Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival. <i>Neuro-Oncology Practice</i> , 2019, 6, 194-202.	1.6	4
35	Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1565-1576.	4.1	11
36	Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T. <i>American Journal of Neuroradiology</i> , 2019, 40, 979-986.	2.4	24

#	ARTICLE	IF	CITATIONS
37	Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. <i>Neurosurgery</i> , 2019, 85, E607-E608.	1.1	20
38	Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. <i>Neuro-Oncology</i> , 2019, 21, 1184-1196.	1.2	28
39	SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. <i>Journal of Neuro-Oncology</i> , 2019, 142, 423-434.	2.9	8
40	Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. <i>Scientific Reports</i> , 2019, 9, 2846.	3.3	32
41	pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 587-595.	2.9	28
42	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	30.7	932
43	Management of low-grade glioma: a systematic review and meta-analysis. <i>Neuro-Oncology Practice</i> , 2019, 6, 249-258.	1.6	52
44	Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. <i>Clinical Cancer Research</i> , 2019, 25, 1913-1922.	7.0	57
45	GPIHBP1 expression in gliomas promotes utilization of lipoprotein-derived nutrients. <i>ELife</i> , 2019, 8, .	6.0	10
46	Risk factors for platelet transfusion in glioblastoma surgery. <i>Journal of Clinical Neuroscience</i> , 2018, 50, 93-97.	1.5	0
47	Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-echo gradient echo echoplanar imaging (CEST-MAGE-EPI). <i>Magnetic Resonance in Medicine</i> , 2018, 80, 1962-1978.	3.0	38
48	Maintenance of Certification: Perceptions and Attitudes of Neurosurgeons. <i>Neurosurgery</i> , 2018, 83, 835-842.	1.1	3
49	Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1195-1203.	0.8	45
50	Rationale and design of the 500-patient, 3-year, and prospective Vigilant Observation of Gliadel Wafer ImplanT registry. <i>CNS Oncology</i> , 2018, 7, CNS08.	3.0	12
51	D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced <i>MIR148A</i> Promoter Methylation. <i>Molecular Cancer Research</i> , 2018, 16, 947-960.	3.4	8
52	Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas. <i>Brain Tumor Pathology</i> , 2018, 35, 1-9.	1.7	12
53	Next-Generation Sequencing and Personalized Medicine for Brain Cancer. <i>Current Surgery Reports</i> , 2018, 6, 1.	0.9	0
54	Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 139, 651-659.	2.9	25

#	ARTICLE	IF	CITATIONS
55	Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. <i>Neuro-Oncology</i> , 2018, 20, 1383-1392.	1.2	135
56	Overview of Dendritic Cell Vaccines for Brain Tumors. , 2018, , 681-692.		0
57	First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. <i>Journal of Translational Medicine</i> , 2018, 16, 142.	4.4	376
58	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	7.7	86
59	Cell-Based Immunotherapy of Gliomas. <i>Progress in Neurological Surgery</i> , 2018, 32, 90-100.	1.3	7
60	Improving BO Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation. <i>Tomography</i> , 2018, 4, 123-137.	1.8	16
61	Human <i>TERT</i> promoter mutation enables survival advantage from <i>MGMT</i> promoter methylation in <i>IDH1</i> wild-type primary glioblastoma treated by standard chemoradiotherapy. <i>Neuro-Oncology</i> , 2017, 19, now189.	1.2	65
62	Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 132, 351-358.	2.9	34
63	Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now287.	1.2	128
64	Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. <i>Neuro-Oncology</i> , 2017, 19, 1494-1502.	1.2	168
65	Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II–III diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 134, 177-188.	2.9	118
66	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	16.8	836
67	Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10220-10225.	7.1	79
68	The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017, 547, 311-317.	27.8	787
69	Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. <i>Experimental and Molecular Pathology</i> , 2017, 103, 87-93.	2.1	7
70	Multiple calcifying pseudoneoplasms of the neuraxis (MCAPNON): Distinct entity, CAPNON variant, or old neurocysticercosis?. <i>Neuropathology</i> , 2017, 37, 233-240.	1.2	17
71	The Aging Neurosurgeon: When Is Enough, Enough? Attitudes Toward Ceasing Practice and Testing in Late Career. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1746-1752.	3.0	8
72	Recognized focused practice: Does sub-specialty designation offer value to the neurosurgeon?. <i>PLoS ONE</i> , 2017, 12, e0189105.	2.5	3

#	ARTICLE	IF	CITATIONS
73	Improving care coordination for brain tumor patients through value-based care redesign of a virtual integrated practice unit.. Journal of Clinical Oncology, 2017, 35, 110-110.	1.6	0
74	PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight, 2016, 1, .	5.0	128
75	Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange. American Journal of Neuroradiology, 2016, 37, 1440-1446.	2.4	39
76	Large-scale assessment of the gliomasphere model system. Neuro-Oncology, 2016, 18, 1367-1378.	1.2	82
77	Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3T. NMR in Biomedicine, 2016, 29, 1563-1576.	2.8	51
78	Phase 1 trial of vocimagene amiretorepvec and 5-fluorocytosine for recurrent high-grade glioma. Science Translational Medicine, 2016, 8, 341ra75.	12.4	158
79	Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma. Cancer, 2016, 122, 1718-1727.	4.1	47
80	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	1.6	160
81	TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination. Cancer Immunology Research, 2016, 4, 412-418.	3.4	64
82	Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro-Oncology, 2016, 18, 368-378.	1.2	31
83	Benefit of MGMT methylation in glioblastoma in relation to hTERT promoter mutation.. Journal of Clinical Oncology, 2016, 34, 2006-2006.	1.6	0
84	Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes. Journal of Visualized Experiments, 2015, , .	0.3	0
85	Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. Molecular Cancer, 2015, 14, 189.	19.2	38
86	Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. PLoS ONE, 2015, 10, e0141334.	2.5	52
87	Dendritic cell immunotherapy for brain tumors. Journal of Neuro-Oncology, 2015, 123, 425-432.	2.9	10
88	IMCT-11NEXT GENERATION T CELL RECEPTOR SEQUENCING CAN IDENTIFY, QUANTIFY, AND TRACK TUMOR-SPECIFIC T CELL POPULATIONS BEFORE AND AFTER DENDRITIC CELL VACCINATION IN GLIOBLASTOMA MULTIFORME PATIENTS. Neuro-Oncology, 2015, 17, v109.4-v110.	1.2	0
89	TMIC-04THERAPEUTIC ANTI-GLIOMA IMMUNITY IS DEPENDENT ON VACCINATION-INDUCED T CELL RESPONSES AND INHIBITION OF APC FUNCTION IN THE TUMOR MICROENVIRONMENT. Neuro-Oncology, 2015, 17, v214.8-v215.	1.2	0
90	MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology, 2015, 122, 497-505.	2.9	37

#	ARTICLE	IF	CITATIONS
91	Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. <i>Molecular Imaging and Biology</i> , 2015, 17, 434-442.	2.6	28
92	Introduction: brain tumor immunotherapy. <i>Journal of Neuro-Oncology</i> , 2015, 123, 321-322.	2.9	1
93	HLA Markers DQ8 and DR53 Are Associated With Lymphocytic Hypophysitis and May Aid in Differential Diagnosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4092-4097.	3.6	52
94	Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. <i>Neuro-Oncology</i> , 2015, 17, vii32-vii40.	1.2	21
95	pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. <i>Neuro-Oncology</i> , 2015, 17, 1514-1524.	1.2	96
96	BI-10 * pH-WEIGHTED MRI IN HUMAN GLIOMAS. <i>Neuro-Oncology</i> , 2014, 16, v25-v25.	1.2	0
97	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 174.	5.2	37
98	Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. <i>Neuro-Oncology</i> , 2014, 16, 815-822.	1.2	49
99	Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI. <i>Journal of Neuro-Oncology</i> , 2014, 116, 373-379.	2.9	95
100	C-terminally truncated form of $\beta$ -crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2014, 117, 53-65.	2.9	9
101	Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in IDH1-Mutant Gliomas. <i>Clinical Cancer Research</i> , 2014, 20, 5808-5822.	7.0	30
102	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	1.6	263
103	Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 116, 551-558.	2.9	12
104	Cytokine responsiveness of CD8+ T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. , 2014, 2, 10.		29
105	The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells. , 2014, 2, 8.		42
106	Imaging biomarkers for antiangiogenic therapy in malignant gliomas. <i>CNS Oncology</i> , 2013, 2, 33-47.	3.0	17
107	Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. <i>Nature Genetics</i> , 2013, 45, 253-261.	21.4	324
108	Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. <i>Neuro-Oncology</i> , 2013, 15, 57-68.	1.2	128

#	ARTICLE	IF	CITATIONS
109	An Essential Requirement for the SCAP/SREBP Signaling Axis to Protect Cancer Cells from Lipotoxicity. <i>Cancer Research</i> , 2013, 73, 2850-2862.	0.9	148
110	Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storage. <i>Journal of Neuro-Oncology</i> , 2013, 113, 365-373.	2.9	23
111	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	7.7	146
112	Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. <i>Neuro-Oncology</i> , 2013, 15, 370-381.	1.2	97
113	Comparison of Glioma-associated Antigen Peptide-loaded Versus Autologous Tumor Lysate-loaded Dendritic Cell Vaccination in Malignant Glioma Patients. <i>Journal of Immunotherapy</i> , 2013, 36, 152-157.	2.4	111
114	Optical imaging for brain tissue characterization using relative fluorescence lifetime imaging. <i>Journal of Biomedical Optics</i> , 2013, 18, 060504.	2.6	10
115	Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. <i>Neuro-Oncology</i> , 2013, 15, 382-390.	1.2	38
116	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2927-2935.	1.6	381
117	BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e109.	5.1	284
118	Protective Properties of Radio-Chemoresistant Glioblastoma Stem Cell Clones Are Associated with Metabolic Adaptation to Reduced Glucose Dependence. <i>PLoS ONE</i> , 2013, 8, e80397.	2.5	48
119	Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2012, 14, 333-343.	1.2	74
120	Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. <i>Neuro-Oncology</i> , 2012, 14, 1465-1472.	1.2	35
121	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	27.8	761
122	Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1458-1469.	6.3	56
123	Differential Sensitivity of Glioma- versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors. <i>Cancer Discovery</i> , 2012, 2, 458-471.	9.4	304
124	IDH Mutations in Human Glioma. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 471-480.	1.7	53
125	Endogenous Vaults and Bioengineered Vault Nanoparticles for Treatment of Glioblastomas. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 451-458.	1.7	10
126	Use of Language Mapping to Aid in Resection of Gliomas in Eloquent Brain Regions. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 497-506.	1.7	31



#	ARTICLE	IF	CITATIONS
127	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. <i>Journal of Neuro-Oncology</i> , 2012, 107, 197-205.	2.9	280
128	Ascending dose trials of the safety and tolerability of Toca 511, a retroviral replicating vector encoding cytosine deaminase, in patients with recurrent high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2101-2101.	1.6	1
129	Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients. <i>PLoS ONE</i> , 2012, 7, e32614.	2.5	83
130	High Order Diffusion Tensor Imaging in Human Glioblastoma. <i>Academic Radiology</i> , 2011, 18, 947-954.	2.5	10
131	Knockdown of CypA inhibits interleukin-8 (IL-8) and IL-8-mediated proliferation and tumor growth of glioblastoma cells through down-regulated NF- $\kappa$ B. <i>Journal of Neuro-Oncology</i> , 2011, 101, 1-14.	2.9	46
132	Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway. <i>Journal of Translational Medicine</i> , 2011, 9, 192.	4.4	38
133	Evidence for Sequenced Molecular Evolution of <i>IDH1</i> Mutant Glioblastoma From a Distinct Cell of Origin. <i>Journal of Clinical Oncology</i> , 2011, 29, 4482-4490.	1.6	420
134	Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 1603-1615.	7.0	378
135	Essential Gene Pathways for Glioblastoma Stem Cells: Clinical Implications for Prevention of Tumor Recurrence. <i>Cancers</i> , 2011, 3, 1975-1995.	3.7	16
136	Enhanced Sensitivity to IL-2 Signaling Regulates the Clinical Responsiveness of IL-12-Primed CD8+ T Cells in a Melanoma Model. <i>Journal of Immunology</i> , 2011, 186, 5068-5077.	0.8	22
137	Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2011, 29, 142-148.	1.6	418
138	Autocrine Endothelin-3/Endothelin Receptor B Signaling Maintains Cellular and Molecular Properties of Glioblastoma Stem Cells. <i>Molecular Cancer Research</i> , 2011, 9, 1668-1685.	3.4	38
139	Genomic Landscape of Meningiomas. <i>Brain Pathology</i> , 2010, 20, 751-762.	4.1	124
140	Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. <i>Journal of Neuro-Oncology</i> , 2010, 96, 359-367.	2.9	86
141	Pituitary adenylyl cyclase activating polypeptide inhibits gli1 gene expression and proliferation in primary medulloblastoma derived tumorsphere cultures. <i>BMC Cancer</i> , 2010, 10, 676.	2.6	34
142	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. <i>Nature</i> , 2010, 465, 966-966.	27.8	360
143	Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. <i>Nature Genetics</i> , 2010, 42, 77-82.	21.4	336
144	A Microfluidic Platform for Systems Pathology: Multiparameter Single-Cell Signaling Measurements of Clinical Brain Tumor Specimens. <i>Cancer Research</i> , 2010, 70, 6128-6138.	0.9	106

#	ARTICLE	IF	CITATIONS
145	The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6459-6464.	7.1	99
146	Dendritic Cell Vaccines for Brain Tumors. Neurosurgery Clinics of North America, 2010, 21, 139-157.	1.7	44
147	Cellular and vaccine therapeutic approaches for gliomas. Journal of Translational Medicine, 2010, 8, 100.	4.4	26
148	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9435-9440.	7.1	246
149	Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Journal of Neurosurgery, 2009, 111, 203-210.	1.6	78
150	Proteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in Gliomagenesis. Cancer Cell, 2009, 16, 44-54.	16.8	132
151	Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. Journal of Neuro-Oncology, 2009, 94, 1-19.	2.9	111
152	Neurosphere Formation Is an Independent Predictor of Clinical Outcome in Malignant Glioma. Stem Cells, 2009, 27, 980-987.	3.2	207
153	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 2009, 462, 739-744.	27.8	3,315
154	Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nature Biotechnology, 2009, 27, 77-83.	17.5	210
155	Editors'™ Message to the Readership. Journal of Neuro-Oncology, 2008, 86, 1-1.	2.9	0
156	Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunology, Immunotherapy, 2008, 57, 1279-1289.	4.2	59
157	Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. Journal of Neuroscience Research, 2008, 86, 48-60.	2.9	144
158	Phase II Pilot Study of Bevacizumab in Combination with Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1372-1380.	0.8	169
159	Disruption of the PACAP gene promotes medulloblastoma in ptc1 mutant mice. Developmental Biology, 2008, 313, 359-370.	2.0	48
160	Relationship between Gene Expression and Enhancement in Glioblastoma Multiforme: Exploratory DNA Microarray Analysis. Radiology, 2008, 249, 268-277.	7.3	146
161	Cytomegalovirus Immunity after Vaccination with Autologous Glioblastoma Lysate. New England Journal of Medicine, 2008, 359, 539-541.	27.0	135
162	Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. PLoS Medicine, 2008, 5, e8.	8.4	499

#	ARTICLE	IF	CITATIONS
163	Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2. <i>Clinical Cancer Research</i> , 2007, 13, 2592-2598.	7.0	108
164	Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20007-20012.	7.1	927
165	High-throughput oncogene mutation profiling in human cancer. <i>Nature Genetics</i> , 2007, 39, 347-351.	21.4	927
166	Distinct Transcription Profiles of Primary and Secondary Glioblastoma Subgroups. <i>Cancer Research</i> , 2006, 66, 159-167.	0.9	182
167	Targeting Stem Cells in Brain Tumors. <i>Technology in Cancer Research and Treatment</i> , 2006, 5, 251-260.	1.9	5
168	Current Status of Clinical Trials for Glioblastoma. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 265-281.	0.8	20
169	Central Nervous System Tumor Immunity Generated by a Recombinant <i>Listeria monocytogenes</i> Vaccine Targeting Tyrosinase Related Protein-2 and Real-Time Imaging of Intracranial Tumor Burden. <i>Neurosurgery</i> , 2006, 58, 169-178.	1.1	17
170	Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain. <i>PLoS Medicine</i> , 2006, 3, e485.	8.4	298
171	Primary Glioblastomas Express Mesenchymal Stem-Like Properties. <i>Molecular Cancer Research</i> , 2006, 4, 607-619.	3.4	215
172	The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity. <i>Journal of Immunology</i> , 2006, 176, 157-164.	0.8	193
173	NK and CD4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain. <i>Journal of Immunology</i> , 2006, 177, 8448-8455.	0.8	59
174	Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1481-1494.	2.8	24
175	Bioluminescent Imaging of Melanoma in Live Mice. <i>Journal of Investigative Dermatology</i> , 2005, 125, 159-165.	0.7	48
176	The TLR7 Agonist Imiquimod Enhances the Anti-Melanoma Effects of a Recombinant <i>Listeria monocytogenes</i> Vaccine. <i>Journal of Immunology</i> , 2005, 175, 1983-1990.	0.8	110
177	Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2005, 11, 5515-5525.	7.0	498
178	Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies. <i>Neurological Research</i> , 2005, 27, 692-702.	1.3	15
179	Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. <i>Molecular Brain Research</i> , 2005, 136, 99-103.	2.3	31
180	Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors. <i>New England Journal of Medicine</i> , 2005, 353, 2012-2024.	27.0	1,376

#	ARTICLE	IF	CITATIONS
181	Cellular immunity and immunotherapy of brain tumors. <i>Frontiers in Bioscience - Landmark</i> , 2004, 9, 3124.	3.0	33
182	Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon- $\alpha$ and interferon- $\beta$ treatment of human glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 2004, 100, 310-319.	1.6	74
183	p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. <i>Oncogene</i> , 2004, 23, 1283-1290.	5.9	67
184	Gene Expression Profiling of Gliomas Strongly Predicts Survival. <i>Cancer Research</i> , 2004, 64, 6503-6510.	0.9	659
185	Title is missing!. <i>Journal of Neuro-Oncology</i> , 2003, 64, 21-30.	2.9	4
186	Identification of molecular subtypes of glioblastoma by gene expression profiling. <i>Oncogene</i> , 2003, 22, 2361-2373.	5.9	247
187	Gene expression profiling identifies molecular subtypes of gliomas. <i>Oncogene</i> , 2003, 22, 4918-4923.	5.9	264
188	Immunology and Immunotherapy in Neurosurgical Disease. <i>Neurosurgery</i> , 2003, 53, 144-153.	1.1	39
189	Tumor immunity within the central nervous system stimulated by recombinant <i>Listeria monocytogenes</i> vaccination. <i>Cancer Research</i> , 2002, 62, 2287-93.	0.9	47
190	Hamartin expression and interaction with tuberlin in tumor cell lines and primary cultures. <i>Journal of Neuroscience Research</i> , 2001, 63, 276-283.	2.9	21
191	Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. <i>Journal of Neurosurgery</i> , 1999, 90, 1115-1124.	1.6	224
192	Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF- $\beta$ 2 antisense gene. <i>Neurological Research</i> , 1998, 20, 742-747.	1.3	73
193	Characterization of a novel and potent 5-hydroxytryptamine $1A$ receptor antagonist. <i>Pharmacology Biochemistry and Behavior</i> , 1991, 38, 555-559.	2.9	45